Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia

Mistry, Jayna J, Hellmich, Charlotte, Lambert, Amelia, Moore, Jamie A, Jibril, Aisha, Collins, Angela, Bowles, Kristian M and Rushworth, Stuart A (2021) Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia. Biomarker Research, 9 (1). ISSN 2050-7771

[img]
Preview
PDF (Published_Version) - Accepted Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview

Abstract

Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resulted in a slower tumor progression and a reduced leukemia growth both in vitro and in vivo. These data provide evidence for clinical evaluation of Venetoclax and Daratumumab combination in the treatment of AML.

Item Type: Article
Uncontrolled Keywords: molecular medicine,clinical biochemistry,biochemistry, medical ,/dk/atira/pure/subjectarea/asjc/1300/1313
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 19 May 2021 00:09
Last Modified: 21 Jul 2021 01:47
URI: https://ueaeprints.uea.ac.uk/id/eprint/80047
DOI: 10.1186/s40364-021-00291-y

Actions (login required)

View Item View Item